A Possible Therapeutic Role for Adenosine During Inflammation
Primary Purpose
Endotoxemia
Status
Completed
Phase
Phase 1
Locations
Netherlands
Study Type
Interventional
Intervention
AMPD1 polymorphism
Caffeine infusion
placebo
Sponsored by
About this trial
This is an interventional prevention trial for Endotoxemia focused on measuring Endotoxin, Adenosine, Caffeine, AMPD1 polymorphism
Eligibility Criteria
Inclusion Criteria:
- Healthy male volunteers
Exclusion Criteria:
- Drug-, nicotine-, alcohol abuses
- Tendency towards fainting
- Relevant medical history
Sites / Locations
- Radboud University Nijmegen Medical Centre
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
1
2
3
Arm Description
Endotoxin and AMPD1 polymorphism
Endotoxin and intervention with caffeine
Endotoxin combined with placebo
Outcomes
Primary Outcome Measures
Hemodynamics; heart rate variability
Markers of Inflammation
Cytokines
Sensitivity to norepinephrine
Endothelial-dependent and independent vasorelaxation
Mediators of Vascular reactivity
Markers of endothelial damage and circulating endothelial cells
Urinary excretion of markers of renal injury
Neurologic testing
Adenosine and related nucleotide concentrations.
Additional blood samples will be drawn for measurement of: TLR-expression, Genetics; micro array analyses and determination of intercellular signalling pathways.
Secondary Outcome Measures
Full Information
NCT ID
NCT00513110
First Posted
August 7, 2007
Last Updated
September 30, 2009
Sponsor
Radboud University Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00513110
Brief Title
A Possible Therapeutic Role for Adenosine During Inflammation
Official Title
A Possible Therapeutic Role for Adenosine During Inflammation
Study Type
Interventional
2. Study Status
Record Verification Date
August 2007
Overall Recruitment Status
Completed
Study Start Date
August 2007 (undefined)
Primary Completion Date
August 2008 (Actual)
Study Completion Date
August 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Radboud University Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The adenosine receptor is known for its anti-inflammatory actions and could therefore be a potential target in the treatment of sepsis and septic shock. Stimulation of the adenosine receptor could potentially lead to a decrease in inflammation and tissue damage.
Under normal conditions adenosine is formed either by an intracellular 5'nucleotidase, which dephosphorylates AMP, or by the hydrolysis of S-adenosylhomcysteine by hydrolase. An alternative pathway of AMP degradations is provided by the cytosolic enzyme AMP deaminase (AMPD), which catalyses the irreversible deamination of AMP to inosine monophosphate and ammonia.
In humans four AMPD isoforms have been described, named after the source from which they were initially purified; M (muscle), L (liver), E1 and E2 (erythrocyte), encoded by AMPD1, AMPD2 and AMPD3. Approximately 15-20% of Caucasian and African American individuals are heterozygous or homozygous for the 34C>T variant of AMPD1.
We hypothesize that healthy volunteers who have the polymorphism for AMPD1 have a less severe inflammatory response to LPS and show less (severe) organ failure. This hypothesis is based on the expected higher levels of adenosine in patients with the AMPD1 polymorphism. This hypothesis is strengthened by the fact that patients with coronary artery disease and the AMPD1 polymorphism show improved cardiovascular survival (Anderson JL et al. J Am Coll Cardiol 2000; 36: 1248-52) possibly based on higher adenosine levels by reduced AMPD activity. Furthermore the polymorphism predicts improved clinical outcome in patients with heart failure (Loh E et al. Circulation 1999) also based on a hypothetical elevation of adenosine.
We hypothesize that:
The C34T-polymorphism of the enzyme AMP-deaminase leads to a decreased inflammatory respons and thereby a decrease of LPS-induced tissue damage.
A second hypothesis is based on the antagonism of the adenosine receptor, by caffeine;
Antagonism of the adenosine receptor by caffeine leads to an increased LPS-induced inflammatory reaction and an increase in (subclinical) tissue damage?
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endotoxemia
Keywords
Endotoxin, Adenosine, Caffeine, AMPD1 polymorphism
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
33 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Endotoxin and AMPD1 polymorphism
Arm Title
2
Arm Type
Experimental
Arm Description
Endotoxin and intervention with caffeine
Arm Title
3
Arm Type
Placebo Comparator
Arm Description
Endotoxin combined with placebo
Intervention Type
Genetic
Intervention Name(s)
AMPD1 polymorphism
Intervention Description
Endotoxin 2ng/kg to subjects with a AMPD1 polymorphism
Intervention Type
Drug
Intervention Name(s)
Caffeine infusion
Intervention Description
Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
Endotoxin 2ng/kg combined with saline infusion (0.9%)
Primary Outcome Measure Information:
Title
Hemodynamics; heart rate variability
Time Frame
24 hrs after LPS administration
Title
Markers of Inflammation
Time Frame
24 hrs after LPS administration
Title
Cytokines
Time Frame
24 hrs after LPS administration
Title
Sensitivity to norepinephrine
Time Frame
24 hrs after LPS administration
Title
Endothelial-dependent and independent vasorelaxation
Time Frame
24 hrs after LPS administration
Title
Mediators of Vascular reactivity
Time Frame
24 hrs after LPS administration
Title
Markers of endothelial damage and circulating endothelial cells
Time Frame
24 hrs after LPS administration
Title
Urinary excretion of markers of renal injury
Time Frame
24 hrs after LPS administration
Title
Neurologic testing
Time Frame
24 hrs after LPS administration
Title
Adenosine and related nucleotide concentrations.
Time Frame
24 hrs after LPS administration
Title
Additional blood samples will be drawn for measurement of: TLR-expression, Genetics; micro array analyses and determination of intercellular signalling pathways.
Time Frame
24 hrs after LPS administration
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy male volunteers
Exclusion Criteria:
Drug-, nicotine-, alcohol abuses
Tendency towards fainting
Relevant medical history
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Pickkers, MD,PhD
Organizational Affiliation
Radboud University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Radboud University Nijmegen Medical Centre
City
Nijmegen
State/Province
Gelderland
ZIP/Postal Code
6500 HB
Country
Netherlands
12. IPD Sharing Statement
Citations:
PubMed Identifier
21211004
Citation
Ramakers BP, Riksen NP, van den Broek P, Franke B, Peters WH, van der Hoeven JG, Smits P, Pickkers P. Circulating adenosine increases during human experimental endotoxemia but blockade of its receptor does not influence the immune response and subsequent organ injury. Crit Care. 2011;15(1):R3. doi: 10.1186/cc9400. Epub 2011 Jan 6.
Results Reference
derived
PubMed Identifier
20444270
Citation
van den Boogaard M, Ramakers BP, van Alfen N, van der Werf SP, Fick WF, Hoedemaekers CW, Verbeek MM, Schoonhoven L, van der Hoeven JG, Pickkers P. Endotoxemia-induced inflammation and the effect on the human brain. Crit Care. 2010;14(3):R81. doi: 10.1186/cc9001. Epub 2010 May 5.
Results Reference
derived
Learn more about this trial
A Possible Therapeutic Role for Adenosine During Inflammation
We'll reach out to this number within 24 hrs